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Galectin-3 (Gal-3), a β galactoside-binding lectin, is implicated in the pathogenesis of allergic
airway inﬂammation and allergen-challenged mice deﬁcient in Gal-3 (Gal-3−/−) exhibit
decreased airway recruitment of eosinophils (Eos). Gal-3 is expressed and secreted by
several cell types and can thus function extracellularly and intracellularly to regulate a
variety of cellular responses. We sought to determine the role of Eos-expressed Gal-3 in
promoting Eos trafﬁcking and migration in the context of allergic airway inﬂammation using
bonemarrow (BM)-derived Eos fromwild-type (WT) andGal-3−/− mice. Airway recruitment
of Eos in acute (4 weeks) and chronic (8–12 weeks) allergen-challengedWT mice correlated
with Gal-3 expression in the lungs. BM-derived Eos were found to express Gal-3 on the
cell surface and secrete soluble Gal-3 when exposed to eotaxin-1. Compared to WT Eos,
Gal-3−/− Eos exhibited signiﬁcantly reduced rolling on vascular cell adhesion molecule 1
(VCAM-1) and decreased stable adhesion on intercellular adhesion molecule 1 (ICAM-1)
under conditions of ﬂow in vitro. Evaluation of cytoskeletal rearrangement demonstrated
that relatively fewer adherent Gal-3−/− Eos undergo cell spreading and formation of
membrane protrusions. In addition, cell surface expression of integrin receptor αM (CD11b)
was lower in Gal-3−/− Eos, which is likely to account for their altered adhesive interactions
with VCAM-1 and ICAM-1. Gal-3−/− Eos also exhibited signiﬁcantly decreased migration
toward eotaxin-1 compared to WT Eos irrespective of similar levels of CCR3 expression.
Further, eotaxin-induced migration of WT Eos remained unaffected in the presence of
lactose, suggesting a role for intracellular Gal-3 in regulating Eos migration. Overall, our
ﬁndings indicate that Gal-3 expression in the lungs correlates with Eos mobilization during
allergic airway inﬂammation and signaling involving intracellular Gal-3 and/or secreted Gal-3
bound to the cell surface of Eos appears to be essential for Eos trafﬁcking under ﬂow as
well as for migration.
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INTRODUCTION
Galectins (1–15) are members of a highly conserved family of
animal lectins deﬁned by their afﬁnity for β-galactose-containing
oligosaccharides (Liu et al., 2012a). They do not contain a classi-
cal signal sequence nor a transmembrane domain and are located
intracellularly (cytoplasm and nucleus), but are also present extra-
cellularly (Ochieng et al., 1993; Hughes, 1999; Lefﬂer, 2001).
Because of this, galectins can function extracellularly and intra-
cellularly and thus participate in a variety of pathways regulating
cellular responses such as cell adhesion, migration, proliferation,
differentiation, and apoptosis, and play an important role in acute
and chronic inﬂammation (Liu, 2000; Liu et al., 2012a). Among
galectins, galectin-3 (Gal-3) is unique since it is a chimeric galectin
containingone carbohydrate-recognitiondomain (CRD) linked to
a proline, glycine, and tyrosine rich N-terminal region.
Previous studies have implicated a role for endogenous Gal-
3 in the pathogenesis of allergic airway inﬂammation. In vivo
studies have demonstrated thatGal-3 expression in the lungs is up-
regulated during allergic asthma and Gal-3 deﬁcient (Gal-3−/−)
mice exhibit signiﬁcantly reduced pulmonary eosinophilia and
airway hyperresponsiveness (AHR) in response to acute allergen
[ovalbumin (OVA)] challenge relative to wild-type (WT) mice
(Zuberi et al., 2004). In addition, we have previously shown that
Gal-3−/− mice exposed to chronic allergen (OVA) challenge have
attenuated airway eosinophilia and exhibit less severe remodel-
ing of the airways, i.e., reduced mucus secretion, sub-epithelial
ﬁbrosis, smooth muscle thickness, and peribronchial angiogene-
sis, compared to WT counterparts (Ge et al., 2010). At a cellular
level, studies from our laboratory have demonstrated that Gal-3
is present on the cell surface of human eosinophils (Eos) from
allergic donors at higher levels than Eos from normal subjects
and functions as a cell surface adhesion molecule to support Eos
rolling and adhesion under conditions of ﬂow (Rao et al., 2007).
Overall, these studies suggest that Gal-3 plays a pro-inﬂammatory
role during allergic asthma and chronic allergic airway
inﬂammation.
The recruitment of Eos to inﬂamed tissues involves spe-
ciﬁc and sequential adhesive interactions between cell surface
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adhesion receptors and vascular counter ligands in inﬂamed
blood vessels followed by their sequestration to extravascular
sites (Broide and Sriramarao, 2001, 2008; Rosenberg et al., 2007).
The ligation of integrin receptor α4β1 with vascular cell adhe-
sion molecule 1 (VCAM-1) mediates Eos rolling, adhesion, and
migration, contributing to selective recruitment of Eos (Walsh
et al., 1991; Sriramarao et al., 1994; Yamamoto et al., 2005). In
addition, a role for β1 and β2 integrins in mediating Eos traf-
ﬁcking has been identiﬁed (Barthel et al., 2008). We and others
have shown that, extracellularly or exogenously added Gal-3 can
bind to integrin and other glycoprotein receptors on the cell sur-
face of human Eos to facilitate cell trafﬁcking and activation,
respectively (Rao et al., 2007; Yoon et al., 2007). Since Gal-3 is
secreted by multiple cell types (macrophages, activated T cells),
in vivo, this secreted Gal-3 can bind to glycan ligands on Eos
and exert its effects. In the current study, we have evaluated
the speciﬁc role of Eos-expressed Gal-3, whether intracellu-
lar or extracellular, in mediating Eos trafﬁcking and migration,
especially in the context of the reduced airway eosinophilia
observed in Gal-3−/−deﬁcient mouse models of allergic airway
inﬂammation.
MATERIALS AND METHODS
MOUSE MODEL OF ALLERGIC AIRWAY INFLAMMATION
WT C57BL/6 mice (8–12 weeks) were sensitized and challenged
with OVA (Grade V, Sigma Chemical Co., St Louis, MO, USA) up
to 4weeks as descried previously (Bahaie et al., 2012; acutemodel).
For chronic allergen exposure, acute allergen-challengedmice con-
tinued to receive biweekly challenges for an additional 4 weeks
(8 weeks total allergen exposure; Cho et al., 2010) or 8 weeks
(12 weeks total allergen exposure; Ge et al., 2010; chronic models).
Control mice were sensitized and challenged with phosphate-
buffered saline (PBS) instead of OVA. All studies involving mice
were performed following standards and procedures approved by
the InstitutionalAnimalCare andUseCommittee at theUniversity
of Minnesota.
SAMPLE COLLECTION
Mice were sacriﬁced 24 h after the last allergen challenge. Eos
counts in the broncho alveolar lavage ﬂuid (BALF) were deter-
mined based on morphologic and histologic criteria after staining
withHema3 System (ThermoFisher ScientiﬁcCo., Pittsburgh, PA,
USA). BALF supernatants were stored at −70◦C and lung tissue
was snap-frozen till further evaluation.
MOUSE BONE MARROW Eos
Eos were cultured from bone marrow (BM) of WT C57BL/6 and
Gal-3−/− mice (Ge et al., 2010) as previously described (Dyer
et al., 2008). Cells between day 12 and 15 of culture differentiated
based on Hema 3 staining and evaluated for expression of both
Eos-expressed major basic protein (MBP) and Siglec-F (Bahaie
et al., 2012) were used in studies.
ENZYME-LINKED IMMUNOSORBENT ASSAY
Gal-3 levels in BALF from control and allergen-challenged mice
were evaluated by enzyme-linked immunosorbent assay (ELISA)
using afﬁnity-puriﬁed goat anti-Gal-3 antibody as the cap-
ture antibody and afﬁnity-puriﬁed rabbit anti-Gal-3 antibody as
the primary detection antibody as described previously (Zuberi
et al., 2004).
WESTERN BLOT ANALYSIS
Lung tissue and BM-derived Eos lysates were prepared in radioim-
munoprecipitation assay (RIPA) buffer and total protein in the
supernatants was measured (BCA Protein Assay Kit, Pierce, Rock-
ford, IL, USA). Lung tissue and Eos lysates (20 μg/per lane) as well
as BALF from allergen-challenged mice and Eos culture super-
natants (20 μl/lane) were electrophoresed on 12% Tris-Glycine
gels under reduced conditions. Western blot analysis was car-
ried out with polyclonal antibodies against Gal-3 (1 μg/ml; Liu
et al., 1995) followed by goat anti-rabbit IRDye 800CW (1:8000,
LI-COR Biosciences, Lincoln, NE, USA). For lung tissue and
cell lysates, expression of β-actin was monitored as an internal
control using anti-mouse β-actin (0.05 μg/ml, BD Transduction
LaboratoriesTM, San Diego, CA, USA) followed by goat anti-
mouse IRDye-680 (1:8000, LI-COR Biosciences). Detection was
carried out with an Odyssey Infrared Imaging System (LI-COR
Biosciences). Densitometry of scanned images was performed
using ImageJ and density of the Gal-3 bands in lung tissue was
normalized against β-actin after background subtraction.
CONFOCAL MICROSCOPY
Bone marrow-derived Eos were cytocentrifuged on to glass slides,
ﬁxed with 4% paraformaldehyde in PBS for 20 min at room
temperature and blocked with 1.5% goat serum in PBS. Cells
were then incubated overnight at 4◦C with mAb against Gal-3
(10 μg/ml, Clone B2C10; Hsu et al., 2000). Bound antibodies were
detected using FITC-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories, Inc., Westgrove, PA, USA). Cells
were stained with 4′,6-diamidino-2-phenylindole (DAPI) to visu-
alize nuclei and examined by confocal microscopy [FLUOVIEW
FV1000/BX61 – Confocal Laser Scanning Biological Microscope
equipped with an UPlanSApo lens (20×/0.85 [oil]) and a PlanApo
N lens (60×/1.42 [oil]), Olympus, Melville, NY, USA] at ambi-
ent temperature. FV10-ASW 2.0 software was used for image
acquisition Olympus.
FLOW CYTOMETRY
To examine surface expression of Gal-3 by BM-derived Eos, non-
permeabilized cells were suspended in cold PBS without Ca2+
and Mg2+ and incubated with polyclonal antibodies against Gal-
3 (10 μg/ml) followed by PE-conjugated goat anti-rabbit IgG
(5 μg/ml, Jackson ImmunoResearch Laboratories, Inc.,) with rab-
bit IgG as the negative control. To examine cell surface receptor
expression, Eos fromWT and Gal-3−/− mice were incubated with
mAbs against CD49d (α4, 10 μg/ml, Clone PS/2; Sriramarao et al.,
1994), CD11a (αL, 10 μg/ml, eBioscience, San Diego, CA, USA),
CD11b (αM, 10 μg/ml, eBioscience), or L-selectin (10 μg/ml,
clone MEL-14; Sriramarao et al., 1994), respectively, followed
by FITC-conjugated goat anti-rat IgG (Jackson ImmunoResearch
Laboratories, Inc.). Rat IgG2b (eBioscience, for α4 and CD11b)
and rat IgG2a (eBioscience, for CD11a and L-selectin)were used as
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isotype-matched controls. For CCR3 expression, Eos were incu-
bated with FITC-conjugated rat anti-mouse CCR3 (2.5 μg/ml,
R&D Systems, Minneapolis, MN, USA) with FITC-conjugated rat
IgG2a (eBioscience) as the isotype-matched control. Cells were
examined using a FACScan ﬂow cytometer (BD Biosciences) and
FlowJo software (version 8.8.2, Tree Star, Ashland, OR, USA).
FLOW CHAMBER ASSAY
Rolling of BM-derived Eos from WT and Gal-3−/− mice on
recombinant mouse (rm) VCAM-1 and intercellular adhesion
molecule 1 (ICAM-1) under conditions of ﬂow (wall shear stress
∼2.0 dynes/cm2; Sriramarao et al., 1996) was evaluated in an in
vitroparallel plate ﬂowchamber as describedpreviously (Rao et al.,
2007; Bahaie et al., 2011). The interaction of Eos with VCAM-1-
and ICAM-1-coated coverslips was observed using a Leitz Wetzlar
inverted microscope and images were recorded for subsequent
ofﬂine analysis to manually determine the number of interacting
cells. Results were expressed as the number of rolling or adherent
cells/2 min.
STATIC ADHESION AND CELL MORPHOLOGY
Bone marrow-derived Eos (1 × 105 cells) from WT or Gal-3−/−
mice were added to rm VCAM-1-coated coverslips (10 μg/ml in
PBS, 100 μl per coverslip) and allowed to adhere for 30 min at
37◦C. Coverslips were washed and adherent cells were ﬁxed with
4% paraformaldehyde in PBS for 20 min. Adherent cells were
stainedwithAlexa Fluor 488 phalloidin as well as DAPI to visualize
nuclei and examined by confocal microscopy as described (Kang
et al., 2012). To assess differences in cell morphology between WT
and Gal-3−/− Eos, adherent cells in ﬁve randomly selected ﬁelds
of each coverslip were counted and the number of cells that exhib-
ited spreading with several membrane protrusions from a round
cell body was identiﬁed and expressed as a percentage of the total
number of adhered cells in the ﬁeld. Results are expressed as per-
cent adhered cells exhibiting change in morphology relative to
WT Eos.
IN VITRO MIGRATION ASSAY
Migration of WT BM-derived Eos in response to eotaxin-1
(100 nM, PeproTech) was evaluated using 96-well Transwell®
Chambers as described previously (Bahaie et al., 2011). In some
experiments, lactose (or maltose as control) at a ﬁnal concentra-
tion of 3 mM was added to the cell suspension to inhibit binding
of secreted/extracellular Gal-3 (Rao et al., 2007; Bahaie et al., 2011)
before placing cells in the chamber. The number of migrated cells
in each case was evaluated after 3–4 h using an Olympus CK2
inverted microscope under a magniﬁcation of 400×. Cells in a
ﬁxed number of randomly selected non-overlapping ﬁelds were
counted for each well for each experiment. The assay was per-
formed three times in duplicate. Results are expressed as percent
cell migration relative to WT Eos or as the average number of
cells/ﬁeld.
STATISTICAL ANALYSIS
Results are expressed asmean± SEM. signiﬁcancewas determined
using the unpaired Student’s t-test. A p value<0.05was considered
as signiﬁcant.
RESULTS
AIRWAY EOSINOPHILIA IN ALLERGEN-CHALLENGED MICE IS
ASSOCIATED WITH ELEVATED Gal-3 EXPRESSION IN THE LUNGS
Differential cell counts in BALF of acute or chronic allergen-
exposed mice indicated increased recruitment of Eos compared
with control mice. Although, the number of Eos in the lungs of
chronic allergen-challenged mice was lower than in acute allergen-
challenged mice, it was still signiﬁcantly higher compared to
corresponding controlmice (Figure 1A). Given thatmice deﬁcient
FIGURE 1 | Airway eosinophilia in allergen-challenged mice is associated
with elevated Gal-3 expression. (A) Eos in BALF of WT C57BL/6 mice after
allergen challenge for 4, 8, or 12 weeks (n = 5 mice/group). (B) Gal-3 levels in
BALF of allergen-challenged and control mice by ELISA (top, n = 6
mice/group) as well as Western blot analysis (bottom). Representative results
for two mice from 4 and 12 week allergen-challenged groups along with
corresponding controls (n = 3–4 mice/group) are shown. (C) Quantitation of
Gal-3 expression in lung tissue of allergen-challenged and control mice by
densitometric analysis of Western blots. Representative results for each
group are shown below (n = 3–4 mice/group). Data represent mean ± SEM.
*p < 0.01 in (A) and (C) and <0.03 in (B) versus control mice; #p < 0.01
versus 4 week allergen-challenged mice in (A).
www.frontiersin.org April 2013 | Volume 4 | Article 37 | 3
“fphar-04-00037” — 2013/4/4 — 14:05 — page 4 — #4
Ge et al. Galectin-3 regulates eosinophil trafﬁcking
FIGURE 2 | Expression and release of Gal-3 by BM-derived mouse Eos.
(A) Cell surface expression of Gal-3 in BM-derived Eos from WT and
Gal-3−/− mice by ﬂow cytometry with rabbit polyclonal antibody against
Gal-3 and rabbit IgG as negative control. (B) Cell surface expression of
Gal-3 in non-permeabilized BM-derived Eos by confocal microscopy using
monoclonal antibodies against Gal-3. Representative images for isotype
control (mouse IgG, top), WT Eos (middle), and Gal-3−/− Eos (bottom) are
shown at a magniﬁcation of 600×. (C) Gal-3 expression in WT and Gal-3−/−
Eos lysates by Western blot analysis using rabbit polyclonal antibodies
against Gal-3. (D) Gal-3 in culture supernatant of Eos incubated with
eotaxin-1 (100 nM) or media alone for 30 min or 6 h by Western blot analysis
followed by densitometry (Mean ± SEM). *p < 0.05 versus Eos cultured
without eotaxin-1 in (D). Representative data of two to four independent
experiments in (A–C) and of three independent experiments in bottom
panel of (D) performed with BM-derived Eos from different mice
is shown.
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in Gal-3 have decreased eosinophilia (Zuberi et al., 2004; Ge et al.,
2010), we ﬁrst evaluated Gal-3 expression in the lungs of allergen-
challengedmice. As previously reported in the case of acute allergic
airway inﬂammation (Zuberi et al., 2004), even chronic allergen-
challenged mice had elevated levels of soluble Gal-3 in the BALF
compared to corresponding control mice as indicated by ELISA
(Figure 1B, top) and Western blot analysis (Figure 1B, bottom).
Although, BALF Gal-3 levels in allergen-challenged mice corre-
lated with airway eosinophilia, being somewhat higher in acute
than in chronic allergen-challenged mice, a statistically signiﬁ-
cant difference between the allergen-challenged groups was not
noted. In addition, Gal-3 expression in the lung tissue of acute
and chronic allergen-challenged mice determined by Western blot
analysis was comparable and signiﬁcantly higher than in corre-
sponding control mice (Figure 1C). These ﬁndings, together with
previous studies demonstratingdecreased eosinophilia in allergen-
challenged Gal-3−/− mice (Zuberi et al., 2004; Ge et al., 2010)
suggest that endogenous Gal-3, whether extracellular (as soluble
protein in BALF) or intracellular (contained within or bound to
surface glycan ligands of certain cell types in lung tissue), is crit-
ically involved in Eos recruitment to the airways of acute and
chronic allergen-challenged mice.
MOUSE Eos EXPRESS Gal-3
While Gal-3 is known to be expressed on the cell surface of human
Eos (Rao et al., 2007) and BALF Eos in allergen-challenged mice
(Ge et al., 2010), thus far there are no studies demonstrating
expression of Gal-3 by BM-derived mouse Eos. In order to further
investigate the potential role of endogenous Eos-expressed Gal-3
in mediating Eos trafﬁcking and recruitment, we ﬁrst established
that mouse BM-derived Eos from naïve mice (non-allergen-
challenged) express Gal-3. Non-permeabilized BM-derived Eos
from WT mice were found to be positive for Gal-3 expression
when stained with polyclonal antibodies against Gal-3 and exam-
ined by ﬂow cytometry relative to Eos from Gal-3−/− mice
stained with the same antibody or Eos stained with normal IgG
which served as negative controls (Figure 2A). These studies
were conﬁrmed by confocal microscopy which demonstrated the
presence of Gal-3 on the cell surface of non-permeabilized WT
BM-derived Eos, but not Gal-3−/− Eos (Figure 2B). Further,
WT BM-derived Eos lysates analyzed for Gal-3 expression by
Western blot analysis displayed a band of 29 kDa correspond-
ing to the reported molecular mass for Gal-3 (Hsu et al., 2000;
Figure 2C).
Since allergic airway inﬂammation is associated with ele-
vated levels of soluble Gal-3 levels in the BALF (Figure 1B), we
investigated whether activated Eos are a source for Gal-3. WT BM-
derived Eos were cultured in medium alone (control) or medium
containing eotaxin-1 for different time intervals and cell culture
supernatants were analyzed for Gal-3 by Western blot analysis.
After 30 min, Gal-3 levels were almost similar in the culture super-
natant of eotaxin-1-treated and untreated Eos; however, after
6 h, there was a signiﬁcant increase in secreted Gal-3 levels in
the culture supernatant of eotaxin-1-treated Eos relative to cor-
responding control supernatant (Figure 2D, p < 0.05). These
ﬁndings conﬁrm that BM-Eos express Gal-3 intracellularly which
is secreted when cells are activated.
FIGURE 3 | Gal-3 deficient Eos exhibit decreased trafficking and
altered cell morphology after adhesion. (A) Rolling and (B) adhesion of
BM-derived Eos from WT and Gal-3−/− mice on rmVCAM-1- and
rmICAM-1-coated coverslips under conditions of ﬂow (∼2.0 dynes/cm2) in
an in vitro ﬂow chamber. (C) BM-derived Eos from WT and Gal-3−/− mice
adherent on rmVCAM-1-coated coverslips were stained with Alexa Fluor
488 phalloidin and DAPI and examined by confocal microscopy. Adherent
cells in ﬁve randomly selected ﬁelds of each coverslip were counted and
the number of cells that exhibited spreading and membrane protrusions
from a round cell body was identiﬁed and expressed as a percentage of the
total number of adhered cells in that ﬁeld. Results presented are relative to
WT Eos. Combined data (mean ± SEM) of two to three independent
experiments is shown in (A–C). *p < 0.05 versus PBS-coated coverslips;
#p < 0.05 versus WT Eos.
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FIGURE 4 | Gal-3 deficient Eos express decreased levels of αM.
Expression of CD11b (αM), CD11a (αL), L-selectin, and CD49d (α4) on the cell
surface of WT and Gal-3−/− Eos was examined by ﬂow cytometry using rat
mAbs against CD11b, CD11a, CD49d, and L-selectin, respectively, followed by
FITC-conjugated goat anti-rat IgG. Rat IgG2b (for CD11b and CD49d) and rat
IgG2a (for L-selectin and CD11a) were used as isotype-matched control
antibodies. Representative data of two to ﬁve independent experiments with
Eos from different mice is shown.
Eos-EXPRESSED Gal-3 IS REQUIRED FOR EFFICIENT Eos ROLLING AND
ADHESION UNDER CONDITIONS OF FLOW
Leukocyte–endothelial interactions play a crucial role in cellu-
lar recruitment to sites of inﬂammation. Our previous studies
have identiﬁed a role for cell surface-expressed Gal-3 in sup-
porting human Eos rolling and adhesion via interaction with
vascular endothelial adhesion molecule VCAM-1 under condi-
tions of ﬂow (Rao et al., 2007). Since Gal-3 secreted by other
cells (in addition to Eos) can also bind to glycan ligands on Eos
and mediate these effects, these studies do not reveal whether
Eos-expressed Gal-3 participates in Eos trafﬁcking. We examined
rolling of WT and Gal-3−/− BM-derived Eos on immobilized rm
VCAM-1 or rm ICAM-1 under conditions of ﬂow (Figure 3A).
WT Eos exhibited a two-fold increase in rolling (p < 0.01) on cov-
erslips coated with rmVCAM-1 compared to background rolling
on PBS-coated coverslips. In contrast, rolling of Gal-3−/− Eos
on VCAM-1 was only marginally higher than background rolling
on PBS-coated coverslips and was signiﬁcantly lower compared
to WT Eos (p < 0.01; Figure 3A). Rolling of both WT and Gal-
3−/− Eos on rmICAM-1, a molecule that does not support rolling,
was similar to that observed on PBS. With respect to stable adhe-
sion under conditions of ﬂow, Gal-3−/− Eos tended to adhere
less effectively on ICAM-1 than WT Eos, although the difference
was not statistically signiﬁcant (Figure 3B). These data suggest
that Eos-expressed Gal-3 is required for efﬁcient Eos rolling on
VCAM-1 and probably adhesion to ICAM-1 under conditions
of ﬂow.
Since Gal-3−/− Eos exhibit decreased adhesive interactions
with vascular endothelial adhesion molecules, we investigated
whether Gal-3 plays a role in regulating cell morphology when
Eos are allowed to interact with VCAM-1 under static conditions.
WT and Gal-3−/− Eos adherent on rmVCAM-1-coated coverslips
were examined by confocal microscopy after phalloidin staining.
A larger number of adherentWT Eos exhibited cell spreading with
several membrane protrusions compared to adherent Gal-3−/−
Eos. In contrast, several Gal-3−/− Eos retained a round cell body
with limited membrane protrusions and spreading. Quantitation
of these differences in cell morphology of adherent WT and Gal-
3−/− Eos revealed that, relative to WT Eos, a smaller percentage
of Gal-3−/− Eos exhibit changes in cell morphology upon adhe-
sion toVCAM-1 (Figure 3C), suggesting that Gal-3 is required for
activation-induced morphological changes that are essential for
directed movement of cells.
Gal-3 DEFICIENCY RESULTS IN DECREASED CELL SURFACE
EXPRESSION OF αM BY Eos
Eos rolling and adhesion are mediated by multiple cell sur-
face adhesion molecules. While our studies demonstrate a direct
requirement for Eos-expressed Gal-3 in mediating Eos rolling
and adhesion, we wanted to determine whether Gal-3 regulates
the expression of cell surface adhesion molecules that promote
Eos rolling and adhesion such as α4, L-selectin, αL, and αM
(Figure 4). There was no difference in expression levels of L-
selectin, α4, and αL between WT and Gal-3−/− Eos. However,
expression of αM by Gal-3−/− Eos was considerably lower than by
WT Eos.
Eos-EXPRESSED Gal-3 IS REQUIRED FOR Eos MIGRATION
In vitro chemotaxis assays were performed to investigate whether
Eos-expressed Gal-3 is essential for eotaxin-1-induced migration
of Eos (Figure 5A). Relative to WT Eos, Gal-3−/− Eos exhibited
signiﬁcantly decreased migration toward eotaxin-1 (p < 0.05).
Expression of CCR3, the eotaxin-1 receptor, by WT and Gal-3−/−
Eoswas evaluated byﬂowcytometry and found to be similar inWT
and Gal-3−/− Eos (Figure 5B), indicating that decreased migra-
tion of Gal-3−/− Eos is not due to reduced cell surface expression
of CCR3. To conﬁrm the involvement of intracellular Gal-3 in
promoting eotaxin-1-induced migration,WT Eos were exposed to
eotaxin-1 in thepresence of lactose to blockbindingof any secreted
Gal-3 to cell surface glycoproteins which could then induce migra-
tion. Migration of WT Eos in the presence of lactose was similar
to that of untreated Eos or Eos treated with maltose (as control;
Figure 5C). These studies suggest that intracellular Gal-3, rather
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FIGURE 5 | Gal-3 deficient Eos exhibit decreased migration toward
eotaxin-1. (A) Migration of WT and Gal-3−/− BM-derived Eos toward
murine eotaxin-1 (100 nM) in vitro using 96-well Transwell® Chambers.
Results are represented as percent cell migration relative to WT Eos. (B)
Expression of CCR3 by WT and Gal-3−/− Eos by ﬂow cytometry using
FITC-conjugated rat anti-mouse CCR3 with FITC-conjugated rat IgG2a as
isotype control. Representative data of two independent experiments with
Eos from different mice is shown. (C) Migration of WT Eos suspended in
medium alone or medium containing lactose or maltose toward murine
eotaxin-1. Number of cells that migrated in each case was determined and
expressed as the average number of cells/ﬁeld. Combined data
(mean ± SEM) from three independent experiments in duplicate is shown
in (A) and (C). #p < 0.05 versus WT Eos in (A).
than extracellular (secreted) Gal-3–glycan interactions, regulates
Eos migration.
DISCUSSION
Studies using mouse models have clearly demonstrated that
endogenous Gal-3 plays a pro-inﬂammatory role during allergic
asthma and chronic allergic airway inﬂammation (Zuberi et al.,
2004; Ge et al., 2010). In these studies, relative to WT mice, devel-
opment of allergen-induced airway eosinophilia, inﬂammation,
AHR, and remodeling were all signiﬁcantly attenuated in mice
that were deﬁcient in Gal-3. In the present study, we found that
airway eosinophilia in acute and chronic allergen-challenged mice
is accompanied with elevated levels of extracellular soluble Gal-3
in the BALF as well as cell associated and/or intracellular Gal-3 in
the lung tissue. While Eos are the predominant inﬂammatory cells
in the airways of allergen-challengedmice, inﬂammatory cells such
as macrophages and T lymphocytes recruited to allergic airways
are known to express and release Gal-3 (Liu et al., 1995; Joo et al.,
2001). Our current studies suggest thatmouse Eos also secreteGal-
3, especially when exposed to eotaxin-1, which together with the
Gal-3 expressed and released by other inﬂammatory cells, accounts
for the elevated levels of this molecule in the airway secretion
during allergic inﬂammation.
Based on previous in vivo studies with Gal-3−/− mice, Gal-
3 appears to be required for recruitment of Eos to the airways
in response to allergen challenge (Zuberi et al., 2004; Ge et al.,
2010). While human Gal-3 is known to be a chemoattractant for
macrophages (Sano et al., 2000), there is no evidence suggesting
thatGal-3 can functiondirectly as a chemoattractant forEos. How-
ever, extracellularly, Gal-3 is known to bind to α4β1 on the cell
surface of human Eos and function as an adhesion molecule to
promote trafﬁcking (rolling and adhesion) in vitro by interacting
with VCAM-1 (Rao et al., 2007). Since Gal-3 is secreted by several
cell types including Eos as shown here, secreted Gal-3 can bind to
its glycan ligands on the Eos surface to mediate these events. We
sought to determine the role of Eos-expressed Gal-3 (without the
inﬂuence of secreted Gal-3 from other cells) speciﬁcally in regulat-
ing Eos trafﬁcking andmigration. BM-derived Eos fromGal-3−/−
mice rolled poorly on VCAM-1 relative to WT Eos under condi-
tions of ﬂow irrespective of similar level of expression of rolling
receptors such as α4 and L-selectin in the two cell types indicating
the requirement of Eos-expressed Gal-3 for efﬁcient Eos rolling.
Once localized on the cell surface, not only can Gal-3 interact
directly with VCAM-1 (Tadokoro et al., 2009), but Gal-3 binding
to α4 (Rao et al., 2007) may be necessary for efﬁcient α4–VCAM-1
interaction, thus resulting in poor cellular rolling when Gal-3 is
absent. In addition, Gal-3−/− Eos tended to adhere less efﬁciently
to ICAM-1 than didWT Eos under conditions of ﬂow, and consis-
tent with this, expressed lower levels of integrin αM, the receptor
that is known to mediate stable adhesion of Eos. Gal-3 has been
shown to facilitate αM clustering on the cell surface (in lipid rafts)
of Eos by cross-linking CD66b which is physically and constitu-
tively associated with αM, thus promoting adhesion (Yoon et al.,
2007). It is possible that in the absence of CD66b cross-linking by
Gal-3, membrane localization of αM may be affected resulting in
decreased adhesion. On the other hand, intracellular Gal-3 may
regulate cell surface expression of αM. This is indeed the case for
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epidermal growth factor receptor (EGFR), where cytosolic Gal-3
was found to play a role in controlling intracellular trafﬁcking and
cell surface expression of this receptor to promote migration of
keratinocytes. In the absence of Gal-3, the surface levels of EGFR
are markedly reduced, with the receptor accumulating diffusely in
the cytoplasm (Liu et al., 2012b).
In addition to poor rolling and decreased adhesion, Gal-3−/−
Eos adherent on VCAM-1 exhibited limited spreading and for-
mation of membrane protrusions compared to WT Eos which
may result in cell detachment under conditions of shear ﬂow as
evidenced by the reduced number of Gal-3−/− Eos adherent on
ICAM-1 in ﬂow chamber assays. These differences in cell mor-
phology of Gal-3−/− Eos compared to WT Eos could be due to
impaired cytoskeletal changes. Activation-induced changes in cell
morphology enable spreading, stable cell adhesion and directed
movement in response to a chemotactic gradient (Ridley et al.,
2003; Rose et al., 2007; Huveneers and Danen, 2009). Consis-
tent with the decreased spreading, the ability of Gal-3−/− Eos to
migrate in response to eotaxin-1 was signiﬁcantly compromised.
The level of expression of CCR3, however, was similar in Gal-
3−/− and WT Eos. Further, exposure of WT Eos to eotaxin-1 in
the presence of lactose to prevent binding of any secreted Gal-3
did not alter migration suggesting that Eos migration is likely to
be regulated by intracellular rather than extracellular Gal-3, thus
accounting for the decreased migration of Gal-3−/− Eos. A role
for intracellular Gal-3 in regulating cell migration has also been
demonstrated in various cancer cells by silencing Gal-3 expression
(Kimet al., 2010;Wang et al., 2012; Zhang et al., 2013). Overall, sig-
naling involving intracellular Gal-3 and/or secreted Gal-3 bound
to the cell surface of Eos appears to be essential for Eos trafﬁcking
under ﬂow and migration.
Not much is known regarding the role of intracellular Gal-3 in
cell trafﬁcking and migration. Kinases such as ERK2 and p38 are
activated during eotaxin-1-induced Eos migration (Kampen et al.,
2000) and in pancreatic cancer cells intracellular Gal-3 has been
shown to activate Ras signaling, including down-stream phospho-
rylation of ERK, resulting in increased invasion (Song et al., 2012).
It is possible that intracellular Gal-3 may play a role in Eos traf-
ﬁcking and migration by regulating speciﬁc kinases. In addition,
recent studies indicate that intracellularly Gal-3 is phosphorylated
in ﬁbroblasts and phosphorylation of Gal-3 is not only required
for localization at the cell periphery, an event important for cell
migration (Hsu et al., 2009), but also for secretionof Gal-3 (Menon
et al., 2011). Further, Gal-3 is a known substrate for c-Abl kinase
in tumor cells (Balan et al., 2010). Taken together, it is possible that
kinase activity is involved in the role played by Gal-3 in Eos traf-
ﬁcking and migration. However, detailed studies in Eos are needed
to determine whether speciﬁc kinases regulate Gal-3 release or if
Gal-3 is phosphorylated in activated Eos and if Gal-3 can poten-
tially regulate other intracellular signaling molecules to affect Eos
trafﬁcking and migration. Finally, intracellular and extracellular
Gal-3 is likely to have varied functions due to interaction with
different ligands [interaction with glycans (extracellular) versus
protein–protein interactions (intracellualar)]. For example, bind-
ing of secreted Gal-3 to its glycan ligands (e.g., integrins) on the
cell surface can initiate signaling events such as activation of focal
adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K)
as well as increased F-actin turnover (Lagana et al., 2006). These
are all important signaling events that occur during Eos trafﬁck-
ing (Huveneers and Danen, 2009; Kang et al., 2012) and could
potentially be initiated by binding of Gal-3 to integrins such as
α4β1.
In further support of our previous ﬁndings where allergen-
challenged Gal-3−/− mice have reduced airway eosinophilia, the
current studies clearly establish a role for Eos-expressed Gal-3 in
mediating Eos trafﬁcking and migration in vitro.
ACKNOWLEDGMENT
This work was supported by National Institutes of Health grant
AI35796 to P. Sriramarao.
REFERENCES
Bahaie, N. S., Hosseinkhani, R. M.,
Ge, X. N., Kang, B. N., Ha, S. G.,
Blumenthal,M. N., et al. (2012). Reg-
ulation of eosinophil trafﬁcking by
SWAP-70 and its role in allergic air-
way inﬂammation. J. Immunol. 188,
1479–1490.
Bahaie, N. S., Kang, B., Fren-
zel, E. M., Hosseinkhani, M.
R., Ge, X., Greenberg, Y., et al.
(2011). N-glycans differentially reg-
ulate eosinophil and neutrophil
recruitment during allergic airway
inﬂammation. J. Biol. Chem. 286,
38231–38241.
Balan, V., Nangia-Makker, P., Jung, Y.
S., Wang, Y., and Raz, A. (2010).
Galectin-3: a novel substrate for c-Abl
kinase. Biochim. Biophys. Acta 1803,
1198–1205.
Barthel, S. R., Johansson, M. W.,
McNamee, D. M., and Mosher,
D. F. (2008). Roles of integrin
activation in eosinophil function and
the eosinophilic inﬂammation of
asthma. J. Leukoc. Biol. 83, 1–12.
Broide, D., and Sriramarao, P. (2008).
“Cellular adhesion in inﬂammation”
in Middleton’s Allergy Principles and
Practice, Vol. 1, eds. N. F. Adkin-
son, S. T. Holgate, W. W. Busse, B.
S. Bochner, R. F. Lemanske Jr., N.
F. Adkinson Jr., et al. (Amsterdam:
Mosby), 149–165.
Broide,D.H., and Sriramarao, P. (2001).
Eosinophil trafﬁcking to sites of aller-
gic inﬂammation. Immunol. Rev. 179,
163–172.
Cho, J. Y., Song, D. J., Pham, A., Rosen-
thal, P., Miller, M., Dayan, S., et al.
(2010). Chronic OVA allergen chal-
lenged Siglec-F deﬁcient mice have
increased mucus, remodeling, and
epithelial Siglec-F ligands which are
up-regulated by IL-4 and IL-13. Resp.
Res. 11, 154.
Dyer, K. D., Moser, J. M., Czapiga, M.,
Siegel, S. J., Percopo, C. M., and
Rosenberg,H. F. (2008). Functionally
competent eosinophils differentiated
ex vivo in high purity from normal
mouse bone marrow. J. Immunol.
181, 4004–4009.
Ge, X. N., Bahaie, N. S., Kang, B.
N., Hosseinkhani, R. M., Ha, S.
G., Frenzel, E. M., et al. (2010).
Allergen-induced airway remodel-
ing is impaired in galectin-3 deﬁ-
cient mice. J. Immunol. 185,
1205–1214.
Hsu, D. K., Chernyavsky, A. I., Chen,
H.-Y., Yu, L., Grando, S. A., and Liu,
F.-T. (2009). Endogenous galectin-
3 is localized in membrane lipid
rafts and regulates migration of den-
dritic cells. J. Invest. Dermatol. 129,
573–583.
Hsu, D. K., Yang, R. Y., Pan, Z., Yu,
L., Salomon, D. R., Fung-Leung, W.
P., et al. (2000). Targeted disrup-
tion of the galectin-3 gene results
in attenuated peritoneal inﬂamma-
tory responses. Am. J. Pathol. 156,
1073–1083.
Hughes, R. C. (1999). Secretion
of the galectin family of mam-
malian carbohydrate-binding pro-
teins. Biochim. Biophys. Acta 1473,
172–185.
Huveneers, S., and Danen, E. H.
J. (2009). Adhesion signaling –
crosstalk between integrins, Src and
Rho. J. Cell Sci. 122, 1059–1069.
Joo, H. G., Goedegebuure, P. S.,
Sadanaga, N., Nagoshi,M., von Bern-
storff, W., and Eberlein, T. J. (2001).
Expression and function of galectin-
3, a beta-galactoside-binding protein
in activated T lymphocytes. J. Leukoc.
Biol. 69, 555–564.
Kampen, G. T., Stafford, S., Adachi,
T., Jinquan, T., Quan, S., Grant,
J. A., et al. (2000). Eotaxin induces
degranulation and chemotaxis of
eosinophils through the activation
of ERK2 and p38 mitogen-activated
protein kinases. Blood 95, 1911–1917.
Kang, B. N., Ha, S. G., Ge, X. N.,
Hosseinkhani, M. R., Bahaie, N. S.,
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery April 2013 | Volume 4 | Article 37 | 8
“fphar-04-00037” — 2013/4/4 — 14:05 — page 9 — #9
Ge et al. Galectin-3 regulates eosinophil trafﬁcking
Greenberg, Y., et al. (2012). The
p110δ subunit of PI3K regulates bone
marrow-derived eosinophil trafﬁck-
ing and airway eosinophilia in
allergen-challenged mice. Am. J.
Physiol. Lung Cell Mol. Physiol. 302,
L1179–L1191.
Kim, S. J., Choi, I. J., Cheong, T. C.,
Lee, S. J., Lotan, R., Park, S. H., et al.
(2010). Galectin-3 increases gastric
cancer cell motility by up-regulating
fascin-1 expression. Gastroenterology
138, 1035–1045.
Lagana, A., Goetz, J. G., Cheung,
P., Raz, A., Dennis, J. W., and
Nabi, I. R. (2006). Galectin binding
to Mgat5-modiﬁed N-glycans regu-
lates ﬁbronectin matrix remodeling
in tumor cells. Mol. Cell. Biol. 26,
3181–3193.
Lefﬂer, H. (2001). Galectin structure
and function – a synopsis. Results
Probl. Cell Differ. 33, 57–83.
Liu, F. T. (2000). Galectins: a new family
of regulators of inﬂammation. Clin.
Immunol. 97, 79–88.
Liu, F. T., Hsu, D. K., Zuberi, R. I.,
Kuwabara, I., Chi, E. Y., and Hen-
derson, W. R. Jr. (1995). Expression
and function of galectin-3, a beta-
galactoside-binding lectin, in human
monocytes and macrophages. Am. J.
Pathol. 147, 1016–1028.
Liu, F.-T., Yang, R.-Y., and Hsu, D.
K. (2012a). Galectins in acute and
chronic inﬂammation. Ann. N Y
Acad. Sci. 1253, 80–91.
Liu, W., Hsu, D. K., Chen, H.-Y., Yang,
R.-Y., Carraway, K. L. III, Isseroff,
R. R., et al. (2012b). Galectin-3
regulates intracellular trafﬁcking of
EGFR through Alix and promotes
keratinocytemigration. J. Invest. Der-
matol. 132, 2828–2837.
Menon, S., Kang, C.-M., and Beningo,
K. A. (2011). Galectin-3 secre-
tion and tyrosine phosphorylation
is dependent on the calpain small
subunit, Calpain 4. Biochem. Biophys.
Res. Com. 410, 91–96.
Ochieng, J., Platt, D., Tait, L., Hogan,
V., Raz, T., Carmi, P., et al. (1993).
Structure–function relationship of
a recombinant human galactoside-
binding protein. Biochemistry 32,
4455–4460.
Rao, S. P., Wang, Z., Zuberi, R. I.,
Sikora, L., Bahaie, N. S., Zuraw, B.
L., et al. (2007). Galectin-3 func-
tions as an adhesion molecule to sup-
port eosinophil rolling and adhesion
under conditions of ﬂow. J. Immunol.
179, 7800–7807.
Ridley, A. J., Schwartz, M. A., Burridge,
K., Firtel, R. A., Ginsberg, M. H.,
Borisy, G., et al. (2003). Cell migra-
tion: integrating signals from front to
back. Science 302, 1704–1709.
Rose, D. M., Alon, R., and Ginsberg,
M. H. (2007). Integrin modulation
and signaling in leukocyte adhesion
and migration. Immunol. Rev. 218,
126–134.
Rosenberg, H. F., Phipps, S., and Foster,
P. S. (2007). Eosinophil trafﬁcking in
allergy and asthma. J. Allergy Clin.
Immunol. 119, 1303–1310.
Sano, H., Hsu, D. K., Yu, L., Apgar,
J. R., Kuwabara, I., Yamanaka, T.,
et al. (2000). Human galectin-3 is a
novel chemoattractant formonocytes
and macrophages. J. Immunol. 165,
2156–2164.
Song, S., Ji, B., Ramachandran, V.,
Wang, H., Haﬂey, M., Logsdon, C.,
et al. (2012). Overexpressed galectin-
3 in pancreatic cancer induces cell
proliferation and invasion by bind-
ing Ras and activating Ras sig-
naling. PLoS ONE 7:e42699. doi:
10.1371/journal.pone.0042699
Sriramarao, P., Norton, C. R.,
Borgström, P., DiScipio, R. G.,
Wolitzky, B. A., and Broide, D. H.
(1996). E-selectin preferentially sup-
ports neutrophil but not eosinophil
rolling under conditions of ﬂow in
vitro and in vivo. J. Immunol. 157,
4672–4680.
Sriramarao, P., von Andrian, U. H.,
Butcher, E. C., Bourdon, M. A.,
and Broide, D. H. (1994). L-selectin
and very late antigen-4 integrin pro-
mote eosinophil rolling at physiolog-
ical shear rates in vivo. J. Immunol.
53, 4238–4246.
Tadokoro, T., Ikekita, M., Toda, T.,
Ito, H., Sato, T., Nakatani, R., et al.
(2009). Involvement of galectin-3
with vascular cell adhesion molecule-
1 in growth regulation of mouse
BALB/3T3 cells. J. Biol. Chem. 284,
35556–35563.
Walsh, G. M., Mermod, J.-J., Hartnell,
A., Kay, A. B., and Wardlaw, A.
J. (1991). Human eosinophil
but not neutrophil adherence to
IL-1 stimulated human umbili-
cal vein endothelial cells is α4β1
(very late antigen-4) depen-
dent. J. Immunol. 146, 3419–
3423.
Wang, Y.-G., Kim, S.-J., Baek, J.-H., Lee,
H.-W., Jeong, S.-Y., and Chun, K.-
H. (2012). Galectin-3 increases the
motility of mouse melanoma cells by
regulating matrix metalloproteinase-
1 expression. Exp. Mol. Med. 44,
387–393.
Yamamoto, H., Nagata, M., and
Sakamoto, Y. (2005). CC chemokines
and transmigration of eosinophils
in the presence of vascular
cell adhesion molecule 1. Ann.
Allergy Asthma Immunol. 94,
292–300.
Yoon, J., Terada, A., and Kita, H.
(2007). CD66b regulates adhe-
sion and activation of human
eosinophils. J. Immunol. 179,
8454–8462.
Zhang, D., Chen, Z.-G., Liu, S.-H.,
Dong, Z.-Q., Dalin, M., Bao, S.-
S., et al. (2013). Galectin-3 gene
silencing inhibits migration and
invasion of human tongue cancer
cells in vitro via down-regulating β-
catenin. Acta Pharmacol. Sin. 34,
176–184.
Zuberi, R. I., Hsu, D. K., Kalayci,
O., Chen, H. Y., Sheldon, H.
K., Yu, L., et al. (2004). Crit-
ical role for galectin-3 in airway
inﬂammation and bronchial hyper-
responsiveness in a murine model
of asthma. Am. J. Pathol. 165,
2045–2053.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 18 February 2013; accepted: 18
March 2013; published online: 05 April
2013.
Citation: Ge XN, Ha SG, Liu F-T, Rao
SP and Sriramarao P (2013) Eosinophil-
expressed galectin-3 regulates cell trafﬁck-
ing and migration. Front. Pharmacol.
4:37. doi: 10.3389/fphar.2013.00037
This article was submitted to Frontiers
in Experimental Pharmacology andDrug
Discovery, a specialty of Frontiers in
Pharmacology.
Copyright © 2013 Ge, Ha, Liu, Rao and
Sriramarao. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
www.frontiersin.org April 2013 | Volume 4 | Article 37 | 9
